Sunday, September 27, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 16, 2026

Uterine Fibroid Market Size to Reach USD 9.43 Billion by 2033 with 7.63% CAGR – SNS Insider

View original at globenewswire.com
Uterine Fibroid Market Size to Reach USD 9.43 Billion by 2033 with 7.63% CAGR – SNS Insider Austin, United States, Feb…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The Uterine Fibroid Market will grow at a CAGR of 7.63% over the forecast period 2026-2033

    80% confidence

  • Ambulatory Surgical Centers is expected to grow at the fastest CAGR of 8.43% from 2026 to 2033

    80% confidence

  • Minimally Invasive Procedures is expected to grow at the fastest CAGR of 8.63% from 2026 to 2033

    80% confidence

  • Intramural Fibroids is expected to grow at the fastest CAGR of 8.20% from 2026 to 2033

    80% confidence

  • The Uterine Fibroid Market size was valued at USD 5.26 Billion in 2025 and is projected to reach USD 9.43 Billion by 2033 and grow at a CAGR of 7.63% over the forecast period 2026-2033

    80% confidence

  • Uterine fibroids occur in approximately 70 to 80% of women by the age of 50

    80% confidence

  • Intramural Fibroids is expected to grow at the fastest CAGR of 8.20% from 2026 to 2033

    80% confidence

  • The Uterine Fibroid Market size was valued at USD 5.26 Billion in 2025 and is projected to reach USD 9.43 Billion by 2033 and grow at a CAGR of 7.63% over the forecast period 2026-2033

    80% confidence

  • Hospitals & Clinics dominated with 47.49% market share in 2025

    80% confidence

  • Surgical Procedures dominated with 38.45% in 2025 due to their proven effectiveness, widespread availability, and established clinical use

    80% confidence

  • African American women have a high risk of uterine fibroids, occurring at a younger age with severe symptoms compared to other ethnicities

    80% confidence

  • MRI-Guided Focused Ultrasound expected to grow at the fastest CAGR of 8.83% from 2026 to 2033

    80% confidence

  • Submucosal Fibroids dominated with 36.24% in 2025 due to their high prevalence and significant symptom severity

    80% confidence

  • MRI-Guided Focused Ultrasound (MRgFUS) is expected to grow at the fastest CAGR of 8.83% from 2026 to 2033

    80% confidence

  • The U.S. Uterine Fibroid Market size was valued at USD 1.78 Billion in 2025 and is projected to reach USD 3.11 Billion by 2033, growing at a CAGR of 7.25%

    80% confidence

  • Minimally Invasive Procedures expected to grow at the fastest CAGR of 8.63% from 2026 to 2033

    80% confidence

  • MRI-Guided Focused Ultrasound (MRgFUS) is expected to grow at the fastest CAGR of 8.83% from 2026 to 2033

    80% confidence

  • Laparoscopic Surgery dominated with 36.58% in 2025 due to its widespread adoption, proven safety, and effectiveness

    80% confidence

  • Healthcare expenditures in developing regions have grown by an approximate 45% over the last decade

    80% confidence

  • Asia Pacific is expected to grow at the fastest CAGR from 2026-2033 in the Uterine Fibroid Market

    80% confidence

  • The U.S. Uterine Fibroid Market size was valued at USD 1.78 Billion in 2025 and is projected to reach USD 3.11 Billion by 2033, growing at a CAGR of 7.25% during 2026-2033

    80% confidence

  • North America is predicted to hold a 45.32% market share in 2025 for uterine fibroids

    80% confidence

  • African American women have a high risk of uterine fibroids, occurring at a younger age with severe symptoms compared to other ethnicities

    80% confidence

  • Surgical Procedures dominated with 38.45% market share in 2025

    80% confidence

  • Asia Pacific is expected to grow at the fastest CAGR from 2026-2033 in the Uterine Fibroid Market

    80% confidence

  • Submucosal Fibroids dominated with 36.24% market share in 2025

    80% confidence

  • Ambulatory Surgical Centers expected to grow at the fastest CAGR of 8.43% from 2026 to 2033

    80% confidence

  • African American women have a high risk of uterine fibroids, occurring at a younger age with severe symptoms compared to other ethnicities

    80% confidence

  • Laparoscopic Surgery dominated with 36.58% in 2025 due to its widespread adoption, proven safety, and effectiveness

    80% confidence

  • Minimally invasive techniques, including laparoscopic myomectomy, uterine artery embolization, and MRI-guided focused ultrasound, have seen adoption rates rise by more than 60% in the past five years

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Vertical AI Agents Attract a Funding Wave Across Fintech-Adjacent Industries
A cluster of AI-native startups applying autonomous agents to narrow, operational problems — hotel front-desk staffing (Dextr AI), identity/fraud risk for financial institutions (Baselayer), insurance distribution (Napo, Connie Health, MGT Insurance) — closed seed-to-Series A rounds within days of each other in September 2026, with CB Insights running a coordinated CEO interview series to spotlight them. The pattern points to agentic AI maturing from generic chat tools into vertical, revenue-generating products, with identity verification for AI agents themselves (Baselayer) emerging as a new fintech infrastructure category responding directly to AI-driven fraud risk.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,984
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,984 facts checked against source5,306 source documents archived
Query this data → isubstrate.com
Uterine Fibroid Market Size to Reach USD 9.43 Billion by 2033 with 7.63% CAGR – SNS Insider — Source | Via News | Via News